Redmile Group LLC increased its stake in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 718.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,254,342 shares of the company’s stock after buying an additional 1,101,025 shares during the period. Diplomat Pharmacy makes up 1.3% of Redmile Group LLC’s holdings, making the stock its 29th largest position. Redmile Group LLC owned approximately 1.88% of Diplomat Pharmacy worth $20,007,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new position in Diplomat Pharmacy during the fourth quarter valued at $2,730,000. Comerica Bank boosted its position in Diplomat Pharmacy by 2.9% in the fourth quarter. Comerica Bank now owns 46,130 shares of the company’s stock valued at $649,000 after buying an additional 1,293 shares during the period. Cipher Capital LP bought a new position in Diplomat Pharmacy during the fourth quarter valued at $211,000. State Street Corp boosted its position in Diplomat Pharmacy by 14.8% in the fourth quarter. State Street Corp now owns 1,089,708 shares of the company’s stock valued at $13,730,000 after buying an additional 140,743 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Diplomat Pharmacy by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 303,696 shares of the company’s stock valued at $3,827,000 after buying an additional 11,902 shares during the period. Institutional investors own 72.82% of the company’s stock.
Shares of Diplomat Pharmacy, Inc. (NYSE DPLO) traded up 2.66% on Monday, reaching $18.52. 455,246 shares of the company traded hands. The firm has a 50-day moving average price of $17.54 and a 200 day moving average price of $15.10. The company has a market capitalization of $1.24 billion, a PE ratio of 73.78 and a beta of 0.62. Diplomat Pharmacy, Inc. has a one year low of $12.25 and a one year high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, May 8th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.04. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Diplomat Pharmacy had a net margin of 0.38% and a return on equity of 7.91%. Diplomat Pharmacy’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.23 EPS. Equities analysts forecast that Diplomat Pharmacy, Inc. will post $0.65 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Diplomat Pharmacy, Inc. (DPLO) Shares Bought by Redmile Group LLC” was reported by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/diplomat-pharmacy-inc-dplo-shares-bought-by-redmile-group-llc/1043592.html.
DPLO has been the subject of several research analyst reports. Mizuho reiterated a “neutral” rating and issued a $17.00 price target on shares of Diplomat Pharmacy in a report on Wednesday, March 1st. Cowen and Company upped their price target on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the company a “market perform” rating in a report on Tuesday, May 9th. Barclays PLC set a $20.00 price target on shares of Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, May 9th. Leerink Swann reiterated a “market perform” rating and issued a $18.00 price target (up previously from $16.00) on shares of Diplomat Pharmacy in a report on Wednesday, May 17th. Finally, Bank of America Corporation upped their price target on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a report on Thursday, May 25th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. Diplomat Pharmacy has a consensus rating of “Hold” and a consensus price target of $21.07.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with our FREE daily email newsletter.